This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Richardson, K Articles by Troke, P F Search for Related Content PubMed PubMed Citation Articles by Richardson, K Articles by Troke, P F

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1985 May; 27(5): 832-835

Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

K Richardson, K W Brammer, M S Marriott and P F Troke

ABSTRACT

The therapeutic potential of UK-49,858, a difluorophenyl bis-triazole derivative, has been assessed by evaluating its activity against systemic infections with Candida albicans in normal mice and rats and in mice with impaired defence mechanisms, against vaginal infections with C. albicans in mice, and against dermal infections with Trichophyton mentagrophytes in guinea pigs. Orally administered ketoconazole was used as a comparative agent throughout, and parenterally administered amphotericin B was included in the study of C. albicans systemic infection in normal mice. The activity of UK-49,858 given orally to mice or rats infected systemically with C. albicans was far superior to that of ketoconazole. In addition, UK-49,858 showed activity comparable to that of amphotericin B when given parenterally, although the latter gave more prolonged protection. UK-49,858 was also effective orally in curing experimental candidal vaginitis in mice and trichophytosis in guinea pigs, against which it was approximately 10 times more active than ketoconazole. These data suggest that UK-49,858 may be of value in the treatment of both C. albicans and dermatophyte fungal infections in man.

---

Antimicrob Agents Chemother. 1985 May; 27(5): 832-835

This article has been cited by other articles:

• Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., Lortholary, O. (2006). Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?. J Antimicrob Chemother 57: 384-410 [Abstract] [Full Text]  
• Chami, F., Chami, N., Bennis, S., Trouillas, J., Remmal, A. (2004). Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model. J Antimicrob Chemother 54: 909-914 [Abstract] [Full Text]  
• Sobue, S., Sekiguchi, K., Nabeshima, T. (2004). Intracutaneous Distributions of Fluconazole, Itraconazole, and Griseofulvin in Guinea Pigs and Binding to Human Stratum Corneum. Antimicrob. Agents Chemother. 48: 216-223 [Abstract] [Full Text]  
• O'Day, D. M., Foulds, G., Williams, T. E., Robinson, R. D., Allen, R. H., Head, W. S. (1990). Ocular Uptake of Fluconazole Following Oral Administration. Arch Ophthalmol 108: 1006-1008 [Abstract]